FcγRIIA and FcγRIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma

MeSH terms

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Murine-Derived / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Cyclophosphamide / administration & dosage
• Doxorubicin / administration & dosage
• Female
• Gene Frequency
• Genotype
• Humans
• Logistic Models
• Lymphoma, Large B-Cell, Diffuse / drug therapy*
• Lymphoma, Large B-Cell, Diffuse / genetics*
• Male
• Middle Aged
• Polymorphism, Single Nucleotide*
• Prednisone / administration & dosage
• Receptors, IgG / genetics*
• Remission Induction
• Rituximab
• Survival Analysis
• Treatment Outcome
• Vincristine / administration & dosage